Virginia Commonwealth University/Massey Cancer Center
Claim this profile,
Global Leader in Cancer
Global Leader in Tumors
Conducts research for Leukemia
Conducts research for Breast Cancer
Conducts research for Lymphoma
609 reported clinical trials
53 medical researchers
Summary
Virginia Commonwealth University/Massey Cancer Center is a medical facility located in undefined, undefined. This center is recognized for care of Cancer, Tumors, Leukemia, Breast Cancer, Lymphoma and other specialties. Virginia Commonwealth University/Massey Cancer Center is involved with conducting 609 clinical trials across 690 conditions. There are 53 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Leslie Randall, MD, and Gita V. Massey.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
Andrew Poklepovic, MDVirginia Commonwealth University/Massey Cancer Center4 years of reported clinical research
Expert in Cancer
Expert in Tumors
33 reported clinical trials
82 drugs studied
Sarah W. Gordon, DOVirginia Commonwealth University/Massey Cancer Center7 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
26 reported clinical trials
54 drugs studied
Leslie Randall, MDVCU Massey Cancer Center1 year of reported clinical research
Studies Ovarian Cancer
Studies Cancer
18 reported clinical trials
33 drugs studied
Gita V. MasseyVirginia Commonwealth University/Massey Cancer Center6 years of reported clinical research
Expert in Brain Tumor
Expert in Tumors
17 reported clinical trials
24 drugs studied
Clinical Trials running at Virginia Commonwealth University/Massey Cancer Center
Breast Cancer
Prostate Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Acute Lymphoblastic Leukemia
Leukemia
Multiple Myeloma
Brain Tumor
Lymphoblastic Leukemia-Lymphoma
Gedatolisib + Fulvestrant +/- Palbociclib
for Advanced Breast Cancer
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Recruiting2 awards Phase 311 criteria
Giredestrant + Hormone Therapy
for Early-Stage Breast Cancer
This study is evaluating whether a drug called giredestrant can improve the survival of women with early breast cancer.
Recruiting2 awards Phase 311 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Virginia Commonwealth University/Massey Cancer Center?
Virginia Commonwealth University/Massey Cancer Center is a medical facility located in undefined, undefined. This center is recognized for care of Cancer, Tumors, Leukemia, Breast Cancer, Lymphoma and other specialties. Virginia Commonwealth University/Massey Cancer Center is involved with conducting 609 clinical trials across 690 conditions. There are 53 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Leslie Randall, MD, and Gita V. Massey.